PT - JOURNAL ARTICLE AU - Arruda, E.A.G. AU - Pires-Neto, R.J. AU - Medeiros, M.S. AU - Quirino-Filho, J. AU - Clementino, M. AU - Gondim, R.N.D.G. AU - Magalhães, L.M.V.C. AU - Cavalcante, K.F. AU - Viana, V.A.F. AU - Mello, Liana Perdigão AU - Martins, R.B AU - Santos, A.A. AU - Magalhães, P.J.C. AU - Havt, A. AU - Lopes, N.P. AU - Arruda-Neto, E. AU - Lima, A.A.M. AU - , TI - Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections AID - 10.1101/2021.09.28.21264242 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.28.21264242 4099 - http://medrxiv.org/content/early/2021/09/30/2021.09.28.21264242.short 4100 - http://medrxiv.org/content/early/2021/09/30/2021.09.28.21264242.full AB - This study aimed to evaluate the efficacy and toxicity of tenofovir (TDF) and TDF combined with emtricitabine (TDF/FTC) in patients with mild to moderate COVID-19 infections. We conducted a randomized, double-blind, placebo-controlled clinical trial in patients with clinical suspicion of mild to moderate respiratory infection caused by SARS-CoV-2 who were treated at an outpatient clinic. Patients were randomly recruited to take 10 days of TDF (300 mg/day), TDF (300 mg/day) combined with FTC (200 mg/day) or placebo Vitamin C (500 mg/day). The primary parameter was the score of symptoms and predictive signs of COVID-19, assessed on the seventh day of patient follow-up. From a total of 309 patients with clinical suspicion of SARS-CoV-2, 227 met the inclusion criteria and were randomly distributed into the following groups: (a) 75 (one did not initiate treatment) in the TDF group; (b) 74 in the TDF combined with FTC group; and (c) 77 in the Vitamin C group (placebo). Of the 226 patients, 139 (62%) were positive for SARS-CoV-2. Fever (≥37.8°C), ageusia or dysgeusia, anosmia or dysosmia, and two or more clinical symptoms or signs were significantly associated with SARS-CoV-2 infection. There was no significant change in clinical score based on clinical symptoms and signs between treatment groups. Patients with mild to moderate infection by SARS-CoV-2 had higher concentrations of G-CSF, IL-1β, IL-6 and TNF-α compared to patients without infection. Patients with mild to moderate respiratory infection, with fever (≥37.8°C), loss of smell, loss of taste and two or more symptoms, have a better prediction for the diagnosis of COVID-19. Patients with SARS-CoV-2 showed higher and more persistent proinflammatory cytokines profile compared to patients not infected with SARS-CoV-2. Pharmacological intervention with TDF or TDF combined with FTC did not change the clinical signs and symptoms score in mild to moderate respiratory infection in patients with SARS-CoV-2 compared to the Vitamin C group (placebo).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04712357Funding StatementARTAN-C19 proposal was supported by Rede Virus, Ministerio da science, Tecnology, Inovation e Comunication (MCTIC), Brasilia-DF through CNPq, Process number: 403542/2020-0.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CONEP with registration no. 34 18262.00.0000.5045All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinicalTrials.gov Identifier: NCT04712357